Skip to main content
. 2017 Jan 24;15(1):e04666. doi: 10.2903/j.efsa.2017.4666

Figure 2.

Figure 2

Changes in total sales and in sales of fluoroquinolones and 3rd‐ and 4th‐generation cephalosporins, from 2011 to 2014, for 25 EU/EEA countries (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and United Kingdom) (source: EMA ESVAC, 2016)